Matthew J. Budoff, MD, FACC
Program Director, Division of Cardiology
Los Angeles Biomedical Research Institute

Printed as of 11/10/2026

Disclosures

Personal Commercial (8)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Amarin	Speaker's Bureau	Significant (>= $5,000)	*General Cardiology*
Amgen	Speaker's Bureau	Significant (>= $5,000)	*Prevention*
Boehringer Ingelheim Pharmaceuticals, Inc	Speaker's Bureau	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Eli Lilly and Company	Research/Research Grants *‡ T Plaque*	Significant (>= $5,000)	*General Cardiology*
Eli Lilly and Company	Speaker's Bureau	Significant (>= $5,000)	*General Cardiology*
General Electric	Research/Research Grants *‡ SSF2 Validation study*	Significant (>= $5,000)	*General Cardiology*
Novartis Corporation	Research/Research Grants *‡ Iliad Trial*	Significant (>= $5,000)	*Prevention*
Novo Nordisk Inc.	Speaker's Bureau	Significant (>= $5,000)	*General Cardiology*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (4)

Trial Name	Trial Sponsor	Trial Funding Source
Vesalius	Amgen	Amgen Inc.
Emporer	Boehringer Ingelheim Pharmaceuticals, Inc	
Clear Outcomes	Esperion	
B1481015	Pfizer	Pfizer

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (3)

Year	Case Title	Represented	Description	Compensation
Self				
2013	cardiac treatment	Plaintiff	patient was not worked up for cardiac chest pain and subsequently suffered sudden death	None ($0)
2009	CT scanning and appropriate care	Defendant	The lawsuit was against an internist and cardiologist who allegedly did not treat aggressively enough a patient with calcification.	None ($0)
2006	CT Scanning	Defendant	The defendents (a radiology group and an internist) was sued for not warning a patient with enough emphasis that they were high risk due to an increased calcium level. The case was dismissed before trial.	None ($0)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 8/20/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/20/2026

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 8/20/2026
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 8/20/2026

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.